Womenra is a prescription medication specifically developed to address acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It contains the active ingredient flibanserin, a multifunctional serotonin agonist and antagonist that works centrally to rebalance neurotransmitters associated with sexual interest. Unlike hormonal therapies, Womenra targets the brain’s neurochemistry to help restore natural desire, reduce distress related to low libido, and improve satisfying sexual events. It represents a clinically validated, non-hormonal approach for a complex and often misunderstood condition.

Features

• Active ingredient: Flibanserin 100mg
• Form: Oral tablet
• Mechanism: Multifunctional serotonin receptor agonist and antagonist (5-HT1A agonist, 5-HT2A antagonist)
• Prescription-only status
• FDA-approved for premenopausal women with HSDD
• Non-hormonal mode of action
• Once-daily bedtime administration

Benefits

• Increases desire for sexual activity by modulating central nervous system pathways
• Reduces distress associated with low sexual desire, improving emotional well-being
• Enhances the frequency of satisfying sexual events
• Provides a targeted, non-hormonal treatment option for HSDD
• Supports improved intimacy and relationship satisfaction
• Clinically demonstrated efficacy in randomized controlled trials

Common use

Womenra is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity, causing marked distress or interpersonal difficulty, which is not better accounted for by a comorbid medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. It is intended for use in women who have not previously experienced problems with sexual desire and who experience a significant decrease from their previous level of functioning.

Dosage and direction

The recommended dosage is one 100mg tablet taken orally once daily, at bedtime. Administration at bedtime is recommended to minimize the risk of certain adverse effects such as dizziness, somnolence, and hypotension. Womenra should be taken consistently; it is not intended for use on an as-needed basis. Clinical improvement may be observed after 4 weeks of treatment, with further improvements possible through 24 weeks of continued use. It should not be taken with alcohol or concomitant moderate or strong CYP3A4 inhibitors. The tablet may be taken with or without food.

Precautions

Womenra can cause hypotension and syncope. The risk is increased with alcohol consumption and concomitant use of moderate or strong CYP3A4 inhibitors. Patients should be advised not to consume alcohol during treatment. It may cause central nervous system depression (e.g., somnolence, sedation). Patients should exercise caution when engaging in activities requiring full alertness, such as driving or operating machinery, until they know how Womenra affects them. Use is not recommended in patients with hepatic impairment. Health care providers should assess underlying medical or psychosocial causes of HSDD before initiating treatment.

Contraindications

Womenra is contraindicated in patients who consume alcohol, in those with hepatic impairment, and in patients taking concomitant moderate or strong CYP3A4 inhibitors. It is also contraindicated in pregnant women and during breastfeeding. It should not be used in postmenopausal women or in men. Hypersensitivity to flibanserin or any component of the formulation is a contraindication.

Possible side effects

Common adverse reactions (≥2% incidence and greater than placebo) include:

• Dizziness
• Somnolence (sleepiness)
• Nausea
• Fatigue
• Insomnia
• Dry mouth
• Anxiety
• flushing

Serious side effects may include hypotension, syncope (fainting), and central nervous system depression. Patients should be advised of the potential for these effects and the increased risk with alcohol use.

Drug interaction

Womenra is primarily metabolized by CYP3A4 and, to a lesser extent, by CYP2C19. Concomitant use with moderate or strong CYP3A4 inhibitors (e.g., fluconazole, verapamil, grapefruit juice) is contraindicated due to significantly increased flibanserin exposure and risk of adverse effects. Concomitant use with alcohol significantly increases the risk of hypotension and syncope and is contraindicated. Use with other CNS depressants (e.g., benzodiazepines, opioids, antipsychotics) may potentiate sedation and hypotension. Caution is advised with concomitant weak CYP3A4 inhibitors or CYP2C19 inhibitors.

Missed dose

If a dose is missed, it should be skipped and the regular dosing schedule resumed the following night. Do not take two doses to make up for a missed dose.

Overdose

There is limited clinical experience with overdose. Symptoms may include severe hypotension, syncope, and CNS depression. In case of suspected overdose, symptomatic and supportive measures should be instituted, including monitoring of vital signs and ECG. There is no specific antidote. Hemodialysis is unlikely to be effective due to high protein binding.

Storage

Store at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep in the original container to protect from light and moisture. Keep out of reach of children and pets.

Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Do not disregard professional medical advice or delay in seeking it because of something you have read here.

Reviews

“After struggling with loss of libido for years and the strain it placed on my relationship, my doctor prescribed Womenra. It took about a month, but I gradually noticed my interest returning. The bedtime dosing helped me avoid any daytime drowsiness. It’s been a meaningful change for me.” – Sarah T., 38

“As a clinician, having a non-hormonal option for HSDD is valuable. I’ve prescribed Womenra to appropriate patients with careful counseling about alcohol avoidance and potential side effects. For motivated patients who adhere to precautions, it can be an effective part of a comprehensive approach.” – Dr. Elena R., Gynecologist

“I was skeptical but decided to try Womenra under my doctor’s supervision. The first week I felt a bit dizzy at times, but it subsided. By the second month, I felt more like myself again—less anxious about intimacy and more spontaneously interested. It requires patience and consistency.” – Jasmine L., 41